662 related articles for article (PubMed ID: 32751111)
1. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.
Furue M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751111
[TBL] [Abstract][Full Text] [Related]
2. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.
Vu YH; Hashimoto-Hachiya A; Takemura M; Yumine A; Mitamura Y; Nakahara T; Furue M; Tsuji G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321923
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor.
Takei K; Mitoma C; Hashimoto-Hachiya A; Uchi H; Takahara M; Tsuji G; Kido-Nakahara M; Nakahara T; Furue M
J Dermatol; 2015 Feb; 42(2):171-80. PubMed ID: 25482884
[TBL] [Abstract][Full Text] [Related]
4. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.
van den Bogaard EH; Bergboer JG; Vonk-Bergers M; van Vlijmen-Willems IM; Hato SV; van der Valk PG; Schröder JM; Joosten I; Zeeuwen PL; Schalkwijk J
J Clin Invest; 2013 Feb; 123(2):917-27. PubMed ID: 23348739
[TBL] [Abstract][Full Text] [Related]
5. Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis.
Lee J; Song KM; Jung CH
Phytomedicine; 2021 Jan; 81():153418. PubMed ID: 33302042
[TBL] [Abstract][Full Text] [Related]
6. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling.
Amano W; Nakajima S; Kunugi H; Numata Y; Kitoh A; Egawa G; Dainichi T; Honda T; Otsuka A; Kimoto Y; Yamamoto Y; Tanimoto A; Matsushita M; Miyachi Y; Kabashima K
J Allergy Clin Immunol; 2015 Sep; 136(3):667-677.e7. PubMed ID: 26115905
[TBL] [Abstract][Full Text] [Related]
7. Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis.
Tsuji G; Hashimoto-Hachiya A; Kiyomatsu-Oda M; Takemura M; Ohno F; Ito T; Morino-Koga S; Mitoma C; Nakahara T; Uchi H; Furue M
Cell Death Dis; 2017 Jul; 8(7):e2931. PubMed ID: 28703805
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of FLG, LOR, and IVL Expression by
Hashimoto-Hachiya A; Tsuji G; Murai M; Yan X; Furue M
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29866992
[No Abstract] [Full Text] [Related]
9. Antioxidant Artemisia princeps Extract Enhances the Expression of Filaggrin and Loricrin via the AHR/OVOL1 Pathway.
Hirano A; Goto M; Mitsui T; Hashimoto-Hachiya A; Tsuji G; Furue M
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28892018
[TBL] [Abstract][Full Text] [Related]
10. Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.
Furue M; Hashimoto-Hachiya A; Tsuji G
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683543
[TBL] [Abstract][Full Text] [Related]
11. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.
Kim BE; Leung DY; Boguniewicz M; Howell MD
Clin Immunol; 2008 Mar; 126(3):332-7. PubMed ID: 18166499
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin blocks the IL-13-induced deficiency of Epidermal Barrier Related Proteins via upregulation of miR-143 in HaCaT Keratinocytes.
Jia QN; Zeng YP
Int J Med Sci; 2020; 17(14):2087-2094. PubMed ID: 32922169
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis.
Furue M
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33233866
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides.
Smits JPH; Ederveen THA; Rikken G; van den Brink NJM; van Vlijmen-Willems IMJJ; Boekhorst J; Kamsteeg M; Schalkwijk J; van Hijum SAFT; Zeeuwen PLJM; van den Bogaard EH
J Invest Dermatol; 2020 Feb; 140(2):415-424.e10. PubMed ID: 31344386
[TBL] [Abstract][Full Text] [Related]
15. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
[TBL] [Abstract][Full Text] [Related]
16. Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis.
Furue M; Hashimoto-Hachiya A; Tsuji G
Acta Derm Venereol; 2018 Nov; 98(10):918-923. PubMed ID: 29972223
[TBL] [Abstract][Full Text] [Related]
17. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin.
Pellerin L; Henry J; Hsu CY; Balica S; Jean-Decoster C; Méchin MC; Hansmann B; Rodriguez E; Weindinger S; Schmitt AM; Serre G; Paul C; Simon M
J Allergy Clin Immunol; 2013 Apr; 131(4):1094-102. PubMed ID: 23403047
[TBL] [Abstract][Full Text] [Related]
18. Potential Therapeutic Skin Microbiomes Suppressing
Lee E; Min K; Ahn H; Jeon BN; Park S; Yun C; Jeon H; Yeon JS; Kim H; Park H
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076953
[TBL] [Abstract][Full Text] [Related]
19. Aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2) signalling: A novel therapeutic target for atopic dermatitis.
Hwang J; Newton EM; Hsiao J; Shi VY
Exp Dermatol; 2022 Apr; 31(4):485-497. PubMed ID: 35174548
[TBL] [Abstract][Full Text] [Related]
20. CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3.
Zu Y; Chen XF; Li Q; Zhang ST
Biochem Genet; 2021 Apr; 59(2):531-546. PubMed ID: 33190168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
